Clinical Trial Update: Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma [Phase 1, Phase 2]

View source ↗

Summary

This update reports completion of a Phase 1/2 clinical trial evaluating Imatinib Mesylate in patients with recurrent malignant glioma or meningioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma
• Meningioma

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Brain and Central Nervous System Tumors | Phase 1, Phase 2 | Status: COMPLETED